Hemanext Inc. Announces Significant Milestone with FDA Marketing Authorization for Hemanext ONE®, Hemanext's Innovative Red Blood Cell (RBC) Processing and Storage System

Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food and Drug Administration (FDA).

Related Keywords

United States ,American ,Regina Hartfield ,Ralph Vassallo ,Androulla Eleftheriou ,Andrew Dunham ,Laurel Omert ,David Green ,Hemanext Inc ,Thalassemia International Federation Guidelines ,Sickle Cell Disease Association Of America ,Corporate Partner Program ,American College Of Surgeons ,Us Food Drug Administration ,Thalassaemia International Federation ,American Society Of Hematology ,Drug Administration ,Association For The Advancement Of Blood ,Chief Executive Officer ,Chief Medical Officer ,Transfusion Medicine ,Johns Hopkins University ,Executive Vice President ,Chief Medical ,Scientific Officer ,Premium Corporate ,Sickle Cell Disease Association ,Executive Director ,Blood Cells ,Leukocytes Reduced ,Red Blood Cells ,Blood Cells Leukocytes Reduced ,European Economic Area ,International Federation Guidelines ,